Strategic funding Exploit recent financing milestones to accelerate market expansion and capacity to meet growing demand for CCM therapy, targeting hospital systems and cardiovascular centers with access to new capital.

FDA Breakthrough Leverage the Breakthrough Device designation to engage payer conversations and streamline reimbursement discussions, highlighting improved patient quality of life and potential cost savings for heart failure programs.

Clinical momentum Position ongoing leadership updates and board appointments as signals of scaling operations, inviting collaborations with clinical partners to pilot CCM therapy in larger cardiology and electrophysiology clinics.

Market fit Target mid-sized healthcare systems and specialty hospitals with high heart failure patient volumes where minimally invasive CCM therapy can serve as a differentiated option with favorable outcomes.

Strategic partnerships Identify opportunities to partner with other medical device firms and distributors in the cardiovascular space to broaden adoption, support post-market surveillance, and expand access to CCM therapy globally.